Our priority is to protect and aid the health and safety of our employees, our customers and their patients. That means ensuring our vital products are available when needed. It also means finding new and creative ways to support the frontline healthcare providers working tirelessly to address the COVID-19 pandemic.
Learn More<em>Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.</em>
Read MoreHighlighted excerpts from the <em>Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.</em>
Download PDFDownload and print for your practice: Treatment algorithm based on the Consensus Guidelines.
Download PDFReview the stocking guidelines established by an international expert panel.
Read MoreReview the National Comprehensive Cancer Network Guidelines for treating various cancers.
Read MoreDownload this resource to help you identify the early warning signs for methotrexate toxicity.
Download PDFWatch and learn about the importance of identifying HDMTX toxicity and when to use Voraxaze<sup>®</sup>.
Watch VideoVisit MTXPK.org to see if your patient is clearing MTX as expected. This tool was independently developed by Dr. Laura Ramsey of Cincinnati Children’s Medical Center and lead author of the Consensus Guidelines<sup>5</sup> and provides:<br /> <ul> <li>A free, open-access clinical decision-making tool for monitoring plasma MTX elimination in both adult and pediatric patients</li> <li>No log in required</li> <li>No patient data stored on the website (but can be stored to local computer and browser)</li> <li>Visual display of data shows expected and actual MTX elimination curves along with serum creatinine trend and predicted time to reach discharge threshold levels</li> <li>Patient report can be downloaded and saved as PDFs or printed</li> </ul>
Read MoreWatch leading experts discuss the current landscape of high-dose methotrexate toxicity and treatment options to improve patient outcomes.
Watch NowReview a roundtable discussion between 3 experts about how to identify patients treated with HDMTX who are at risk for developing AKI, the clinical implications of guidelines, and strategies to integrate guidelines into practice.
Watch NowWatch and listen to experts discuss important information about guidelines for managing patients with delayed methotrexate elimination due to renal impairment.
Watch VideoReview the management of delayed MTX elimination due to AKI according to published clinical guidelines using two certified case-based activities of HDMTX toxicity created for oncology advanced practitioners.<br />
Read MoreExamine hospital length of stay, mortality, and readmission rates for Medicare cancer patients with delayed clearance of MTX treated with glucarpidase.
Read MoreA Clinical Decision Support Tool Evaluating High‐Dose Methotrexate Pharmacokinetics to Inform Post‐Infusion Care and Use of Glucarpidase.
Read More